explore -WSS

explore

author：leisure time 2025-09-27 11:58:13 - browse：444

UCB website -- health policy coverage from STAT — Adobe

WASHINGTON — UCB left BIO at the end of 2023, the second major member company to exit after Pfizer pulled out as well.

UCB, headquartered in Belgium, decided not to renew its BIO membership after a routine evaluation of its engagement in trade associations, said company spokesperson Erica Puntel.

Newsletters

Sign up for D.C. Diagnosis

Washington never stops. Cut through the noise with our essential updates on health care politics and policy

Please enter a valid email address. Privacy Policy

Pfizer, whose departure STAT reported first, was listed on BIO’s website as a sponsor at one of the group’s highest levels. Pfizer bought Global Blood Therapeutics, which current BIO Board Chair Ted Love led to the approval of a drug to treat sickle cell disease, in 2022.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Diversity in medical illustrations gets boost from Chidiebere Ibe

hotspot

WSS

6 surprising facts about sugar

Pfizer, Moderna say biotech, pharma drug development is a sprint

Diabetes management: Digital health tools fall short, study says

Radiation, mainstay of cancer treatment, begins a fade

FDA panel gives mixed vote on blood pressure devices

Drug firms test therapies to halt Alzheimer’s before symptoms arise

hotspot

explore

Sign up for D.C. Diagnosis

entertainment

Duchenne breakthrough therapy leaves behind pioneering families

2024 GOP presidential candidates spar over abortion in debate

How one medical school became remarkably diverse

'Patient friction coefficient' can gauge a clinical trial's patient burden

Medicare details structure of new drug price negotiation program

What AAP's gender

Psychedelics group wrestles with new pharma identity

Medical devices makers are asking for forgiveness, not permission

Bright Health sells Medicare Advantage business to Molina

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

entertainment

Readout Newsletter: Illumina, CRISPR, Regeneron

How to make Best Hospitals ratings actually useful for patients

Radiation, mainstay of cancer treatment, begins a fade

With Wegovy coverage, Medicare patients may face high costs

In science, is the line between industry and academia shifting?

Neuroscience startup Neumora files for IPO

explore

hotspot

hotspot

hotspot